Switzerland Archives

Switzerland, Swiss biotech, Biotech Companies, startups

Best in Biotech 9 Jun 2021

Top 15 Swiss biotech startups making a difference in Europe

Switzerland has long been known as a booming biotech hotspot in Europe that boasts many high-profile companies. Here are the top 15 biotech companies among the new generation of promising startups in Switzerland. Last year saw a record-breaking amount of money pouring into the Swiss biotech industry. According to a recent report by the Swiss […]

June 9, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 15 Oct 2020

Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease

Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have been approved in less than a year. Neuromyelitis optica spectrum disorders, previously also known as Devic disease, affect up to 2 in 100,000 people around the world. […]

October 15, 2020 - 3 minutesmins - By Helen Albert

gene therapy cardiac rare disease biomarin dinaqor

News and Trends 7 May 2020

BioMarin Partners Swiss Biotech to Develop Cardiac Gene Therapies

US biotech BioMarin has partnered Swiss startup DiNAQOR to develop gene therapies to treat rare, inherited cardiac diseases. DiNAQOR will initially receive an upfront payment from BioMarin, followed by developmental, regulatory, and commercial milestone payments and a percentage of royalties on later sales. No financial details of the collaboration were revealed by either company. “We […]

May 7, 2020 - 2 minutesmins - By Helen Albert

News and Trends 27 Feb 2020

Scientists Connect Brain Cells to Machines Over the Internet

An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI implants for treating neurological disorders. As described in a study published in Nature Scientific Reports, the team set up a system where cultured rat nerve […]

February 27, 2020 - 3 minutesmins - By Jonathan Smith

novadiscovery in silico clinical trial ai

Startup Scout 14 Feb 2020

Novadiscovery Carries out Clinical Trials using AI and Simulations

Novadiscovery, based in Lyon, France, is developing AI-based simulation technology to predict clinical trial outcomes and cut their running costs. Mission: To predict the outcomes of clinical trials in silico using a combination of artificial intelligence (AI) and computational models of the biology underlying the disease. Clinical trials cost the healthcare industry billions of euros […]

February 14, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 4 Feb 2020

Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not […]

February 4, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 28 Jan 2020

A Future Gene Therapy Could Be Delivered in Tiny ‘Nanocontainers’

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient […]

January 28, 2020 - 3 minutesmins - By Jonathan Smith

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

More News! 10 Dec 2019

ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III

An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […]

December 10, 2019 - 2 minutesmins - By Jonathan Smith

dna data storage self replicating machine

News and Trends 9 Dec 2019

Scientists Use DNA Data Storage to Hide Information in Everyday Objects

Scientists have developed a method for storing DNA data in 3D-printed objects, which could one day allow machines to replicate themselves. The group, based at ETH Zurich, Switzerland, as well as in Israel and the US, began by synthesizing DNA molecules that encode blueprints of the Stanford bunny, a rabbit-shaped object commonly used in testing […]

December 9, 2019 - 4 minutesmins - By Jonathan Smith

lupus autoimmune disease neutrophil citryll

More News! 26 Nov 2019

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

A small molecule drug developed by the US company ChemoCentryx and its Swiss partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) was more effective at treating a rare inflammatory vascular disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition […]

November 26, 2019 - 3 minutesmins - By Jonathan Smith

More News! 18 Sep 2019

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […]

September 18, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us